A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subjects
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as
measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an
active control (phentermine 30 mg).